Oncogene may lead to predictive test

Researchers at The University of Texas MD Anderson Cancer Centre say they have discovered a potential oncongene in ovarian cancer, which is the leading cause of gynaecological cancer death in US women.

They say that levels of the protein produced by this suspected oncongene, known as atypical protein kinase C iota (PKCi), in combination with a second protein, Cyclin E, strongly predict outcome in non-serous ovarian cancer, which accounts for 40% of ovarian cancer cases.

They further report PKCi is over-expressed in serous ovarian cancer, which makes up the remaining 60% of ovarian cancer cases.

Based on these findings, the researchers suggest that PKCi as well as the second protein, Cyclin E, could be used as a powerful predictive test for non-serous ovarian cancer.

They also say that an agent that inhibits PKCi might offer a novel therapy for both forms of the cancer, which is difficult to treat in advanced stages.

This study is the first to find that PKCi plays a role in ovarian cancer, says the study's principal investigator Gordon Mills, a professor and chairman of the Department of Molecular Therapeutics.

More than that, he says, "This is the first direct proof that over-expression of PKCi is sufficient to produce proliferation in ovarian cancer and thus acts as an oncongene."

Mills and the research team, which includes investigators from Lawrence Berkeley National Laboratory and the University of Wisconsin, believe that over-expression of PKCi triggers excess production of Cyclin E, which is known to play a role in cancer growth.

PKCi is a member of a family of PKC kinase proteins that regulates cell-to-cell communication and spatial orientation. While some members of this large family have been associated with cancer, PKCi had not before this study.

Researchers say that PKCi and Cyclin E together contribute to the aggressiveness of ovarian cancer because high levels of the protein are associated with reduced survival.

"This is the strongest predictive combination of markers to determine behaviour of ovarian cancer yet found," Mills says.